Evidence map›Paper›PMID 33939299›Full record

SynthesisActa ophthalmologica2022

Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis.

Marcus C de Jong, Furqan Shaikh, Brenda Gallie, Wijnanda A Kors, Robin W Jansen, Charlotte Dommering, Pim de Graaf, Annette C Moll, Helen Dimaras, Manohar Shroff and 2 more

Open access · hybridAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Acta ophthalmologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Marcus C de JongDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-8524-5108
Furqan ShaikhDepartment of Pediatric Hematology and Oncology, University of Toronto, Toronto, ON, Canada.
Brenda GallieDepartment of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-9697-9211
Wijnanda A KorsDepartment of Pediatric Oncology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Robin W JansenDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Charlotte DommeringDepartment of Clinical Genetics, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pim de GraafDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Annette C MollDepartment of Ophthalmology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-9313-8345
Helen DimarasDepartment of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.
Manohar ShroffDivision of Pediatric Neuroradiology, The Hospital of Sick Children, Toronto, ON, Canada.
Tero T KiveläDepartment of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID https://orcid.org/0000-0003-1198-4394
Sameh E SolimanDepartment of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.
Amsterdam University Medical Centers · NLUniversity of Toronto · CAHospital for Sick Children · CAUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the risk of patients with an early diagnosis of heritable retinoblastoma being diagnosed with TRb (or pineoblastoma) asynchronously in a later stage and its effect on screening.

methodsWe updated the search (PubMed and Embase) for published literature as performed by our research group in 2014 and 2019. Trilateral retinoblastoma (TRb) patients were eligible for inclusion if identifiable as unique and the age at which TRb was diagnosed was available. The search yielded 97 new studies. Three new studies and eight new patients were included. Combined with 189 patients from the previous meta-analysis, the database included 197 patients. The main outcome was the percentage of asynchronous TRb in patients diagnosed before and after preset age thresholds of 6 and 12 months of age at retinoblastoma diagnosis.

resultsSeventy-nine per cent of patients with pineoblastoma are diagnosed with retinoblastoma before the age of 12 months. However, baseline MRI screening at time of retinoblastoma diagnosis fails to detect the later diagnosed pineal TRb in 89% of patients. We modelled that an additional MRI performed at the age of 29 months picks up 53% of pineoblastomas in an asymptomatic phase. The detection rate increased to 72%, 87% and 92%, respectively, with 2, 3 and 4 additional MRIs.

conclusionsAn MRI of the brain in heritable retinoblastoma before the age of 12 months misses most pineoblastomas, while retinoblastomas are diagnosed most often before the age of 12 months. Optimally timed additional MRI scans of the brain can increase the asymptomatic detection rate of pineoblastoma.

Indexed as

Early DiagnosisPineal GlandBrain NeoplasmsHumansInfantMagnetic Resonance ImagingPinealomaRetinal NeoplasmsRetinoblastomamagnetic resonance imagingMRIpineal glandpineoblastomaPNETretinoblastomatrilateral retinoblastoma

Identifiers

PMID33939299
PMCPMC9292554
OpenAlexW3157638396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.